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ABSTRACT
Depression and anxiety are debilitating mental health conditions that affect a large
portion of the United States. Current pharmacological treatments for these disorders require daily
administration, are associated with a number of side effects, and can be ineffective for some.
Emerging evidence in novel treatment options may necessitate a shift toward how we treat these
psychiatric disorders.
Studies involving the psychedelic serotonin agonist, psilocybin, are currently
experiencing a resurgence as an alternative for patients who are unresponsive to traditional
treatments. Clinical trials using psilocybin in combination with psychotherapy have
demonstrated sustained reductions in depression and/or anxiety symptoms. When used in
medical settings, it has shown to be safe, with few side effects and no risk of dependence.
However, this psychedelic compound faces many stigmas and these results have yet to be
compared to current treatments or in larger populations. Psilocybin represents a promising field
of research that warrants more robust studies in order to gain societal approval and establish a
role in treating common psychiatric diagnoses.

INTRODUCTION
Depression is one of the leading causes of disability worldwide.1 According to the
National Institutes of Health (NIH) in 2017, an estimated 17.3 million adults in the United States
had at least one major depressive episode. This number represented over 7% of all U.S. adults.
The total economic burden of major depressive disorder is estimated to be more than $210
billion each year in the U.S.2 Therapy and antidepressants are some of the most commonly used
treatments for depression, but approximately 20% of patients do not respond to any type of

intervention.3,4 Conventional antidepressants such as SSRIs and SNRIs come with undesired side
effects, delayed therapeutic onset, or in some cases a complete lack of response.4,5 In search of
more effective treatment options, scientists are taking a refreshed look at psychedelic
compounds, such as lysergic acid diethylamide (LSD), ayahuasca, and psilocybin, to treat the
growing mental health crisis plaguing our society.
Psilocybin is showing promising results in treating a number of psychiatric disorders
when combined with psychotherapy. While only small studies have been conducted, psilocybin
has safely exhibited rapid and sustained antidepressant and anxiolytic effects after the
administration of just one or two doses.6,7 These results could imply a reduced need for daily
medications with an alleviation of symptoms for weeks or even months. It is important for
today’s medical providers to be informed of the progressing studies involving psilocybin, as they
have the potential to treat patients suffering from depression who have found mainstream
therapies unsuccessful.
This article examines the efficacy of psilocybin and its potential use in treating some of
the most common mental health conditions seen by primary care and behavioral medicine
providers. Other psychedelics are being investigated to treat various psychiatric diseases,
however, this article will only focus on psilocybin use in patients suffering from depression
and/or anxiety. The purpose of this article is not to promote the recreational use of psychedelics
outside of a clinical setting with trained specialists.

BACKGROUND
For thousands of years, psilocybin has been used in religious, medicinal, and ceremonial
practices around the world.8 It was first isolated and synthesized by the Swiss chemist Albert
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Hofmann in 1958.9 At the time of its introduction to Western society, psychiatry lacked effective
medical therapies to treat mood, anxiety, and addictive disorders.9 Researchers quickly
discovered psilocybin had therapeutic potential for treating these conditions and a low risk of
toxicity.9 Hundreds of papers were published displaying the efficacy of psychedelics at treating
non-psychotic mood disorder patients who failed to make progress with medication or therapy.9
However, widespread recreational misuse of psychedelics led to their association with the
counterculture in the 1960s. In 1967, the U.S. declared psychedelics, including psilocybin,
Schedule I drugs.9 Compounds in this classification are deemed to have no accepted medical use
and a high potential for harm and chemical dependence.
Over the last decade, there has been a resurgence of studies using psilocybin in
combination with psychotherapy to treat depression, anxiety, obsessive compulsive disorder
(OCD), addiction, cluster headaches, and most recently anorexia nervosa.

HOW IT WORKS
Psilocybin, commonly known as “magic mushrooms”, is a naturally occurring compound
found in a variety of mushroom species.4,10 Following ingestion, psilocybin is broken down to its
psychoactive metabolite, psilocin (4-hydroxy-N, N-dimethyltryptamine).11 Psilocin acts as an
agonist to 5-HT2A serotonin receptors in the brain.8,11,12 While it is not completely understood,
scientists believe that this interaction is what attributes psilocybin to hallucinogenic and euphoric
effects. By increasing serotonergic signals, psilocybin reduces depression and anxiety, while
increasing positive mood state.12 Functional magnetic resonance imaging (fMRI) evidence
suggests that psilocybin produces these symptoms by affecting the amygdala and an area of the
brain called the default mode network (DMN).12,13 This neuronal network is largely responsible
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for the ego, sense of self, and perceptions of the outside world. Hyperactivity of the DMN has
been linked to negative self-referential and ruminating thoughts commonly associated with
depression and anxiety.4,8,10 By decreasing DMN activity, individuals experience mental
flexibility leading to positive changes in attitude, mood, perspective, values, and behavior.4,12,14
This allows patients to accept their emotions and process them. According to studies, these
effects are rapid and can last long after their session is over, even in conditions notorious for
resistance to treatment.7,10,13,14
In clinical trials, psilocybin is administered to participants in a controlled environment.
Preparatory sessions are performed by trained psychiatrists to discuss patient’s personal history
(including thoughts and origins of depression or anxiety), psychological effects of psilocybin,
and a simulation of the dosing session.13 The psilocybin is delivered in a clear or opaque capsule
and consumed orally. During administration, patients are placed in a supine or relaxed position,
given eyeshades and headphones (to reduce any outside stimuli), and are psychologically
supported whenever needed. Patients are supervised at all times and are assessed periodically
throughout the four to six hour session. After each dosing session, patients attend further visits to
discuss the experience and integration into their life.

FINDINGS
Over the past decade, studies conducted at research institutions like Johns Hopkins
University School of Medicine, New York University, and Imperial College of London have
shown measurable benefits in early trials. In all studies to date, administration resulted in
statistically significant reductions in symptoms and clinical improvements in anxiety or
depression.4 The largest of the completed clinical trials have been on patients who experience
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psychological distress associated with a life-threatening illness. Two double-blind, randomized,
crossover trials investigated the effects of psilocybin on symptoms of depression and anxiety in
patients with terminal cancer.7,14 In 2016, Griffiths et. al studied the effects of psilocybin in
cancer patients (n=51) with life-threatening diagnoses and symptoms of depression and/or
anxiety in a randomized, double-blind, cross-over trial with very low dose versus high dose
psilocybin.14 Two counterbalanced dosing sessions were held five weeks apart and a six month
follow-up was conducted. The study found that the treatment produced large decreases in
depressed mood and death anxiety, along with increases in optimism and quality of life.14 Six
months after their dosing sessions, 78% of the patients with depression and 83% with anxiety
showed persistent symptom remission. Furthermore, 80% of all participants stated that their
experience increased their well-being or life satisfaction.14
A recent open-label pilot study examined psilocybin administration in individuals (n=12)
with treatment-resistant depression. All participants were diagnosed with moderate to severe
depression, lasting on average 17.8 years, and had no improvement despite two or more courses
of antidepressant treatments.13 These patients received an initial safety session of low dose
psilocybin (10 mg), then the second session of a higher dose (25mg) was performed seven days
later.4,13 One week after the administration, 67% of the patients showed a response to treatment
and reduction in their depressive symptoms. Three months after, 58% maintained response, and
42% met criteria for complete remission.13 These results have implications for patients who have
failed to respond to all other forms of therapy and medication currently available and warrant
further study.

SAFETY

5

Clinical studies have shown psilocybin therapy to be well tolerated, safe, and with
minimal side effects.12-15 The most common adverse effects include transient anxiety, nausea,
vomiting, and mild increases in blood pressure and heart rate.6,9 Shortly after medication onset,
patients can experience emotional and perceptual changes that can be varied and intense.
Individuals can often become frightened, disoriented, or more anxious during the treatment.
Fortunately, none of the conducted studies in the last 25 years produced prolonged psychosis,
persisting hallucination, or required any medical intervention.4,6,9 In terms of dependence, there
has been no reported risk.4 Current phase two trials being performed by COMPASS Pathways
are exploring the safety and efficacy of psilocybin in 200 participants and should conclude by the
end of 2020 (ClinicalTrials.gov, number NCT03775200). The potential for abuse, although very
low, is due to repeated daily intake causing downregulation of serotonin receptors and rapid
tolerance.4 In fact, studies of alcohol and smoking cessation indicate psilocybin may have antiaddictive properties.16,17 These findings suggest that it can be safely administered to patients in a
controlled setting.

CONCLUSION
Given the promising results of small clinical trials, psilocybin may have a role in the
treatment of depression and/or anxiety, with some evidence for a role in treatment-resistant
major depressive disorder. Nevertheless, psilocybin remains a Schedule I drug and much of how
it benefits patients remains unknown. As of now, clinical trials have small sample sizes and are
short in duration. Before it is legalized and used in practice, we must be certain of the long-term
effects in larger populations. Additionally, there is a need to conduct contrasting antidepressant

6

studies, such as the ongoing randomized trial comparing psilocybin to the SSRI escitalopram
(ClinicalTrials.gov, number NCT03429075).
As a stigmatized substance, there are regulations that stand in the way of gaining
imperative data, however, we must pursue research in this field to find alternative methods of
alleviating debilitating human conditions. Providers in psychiatry and primary care settings are at
the forefront of helping patients with their mental health ailments. Regardless of the chosen
remedy, we suggest that medical providers remain vigilant in novel treatment options and that
we expand our ‘best practice’ in treating common mental health conditions. Ultimately, these
mushrooms may not be for everyone, but for some, they could be magic.
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